Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: REPL stock price vs EW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EW's multiple
Needs Revenue / share, EW P/S.
Implied fair value · at REPL's multiple
Needs REPL P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: REPL FY 2026 (ended Mar 31, 2026) · EW FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
REPLIMUNE GROUP, INC. · implied price per share
Cash flow and years must be positive.
Edwards Lifesciences Corporation · implied price per share
Bear
$21.79
Base
$25.64
Bull
$29.48
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.50x
0.12x
Net debt / EBITDA
Leverage against operating earnings
0.60x
-2.01x
Cash and equivalents
Liquid reserves on the balance sheet
$268.89M
$4.23B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REPL vs AMGN
INCYTE CORP
REPL vs INCY
Blueprint Medicines Corp
REPL vs BPMC
Adaptive Biotechnologies Corp
REPL vs ADPT
ABBOTT LABORATORIES
REPL vs ABT
JOHNSON & JOHNSON
REPL vs JNJ
Medtronic plc
REPL vs MDT
BOSTON SCIENTIFIC CORP
REPL vs BSX
BAXTER INTERNATIONAL INC
REPL vs BAX
DENTSPLY SIRONA Inc.
REPL vs XRAY
$83.31M
$1.20B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe REPL can materially improve operating performance from its current -$313.9M net income base and move toward profitability, then hold or selectively buy near the lower end of its $10.42-$12.74 range because the current price sits inside historical bounds and the valuation is already reflecting a high-risk profile.
REPL trades within its stated historical band at $11.58, versus a EW that commands a much richer profitability multiple set. However, the valuation comparison is incomplete because REPL has no usable P/S, revenue, or EBITDA base in the provided data, so the discount cannot be cleanly quantified on the same basis as EW.
Supporting Metrics
